Shree Ganesh Remedies Ltd
P&L
Quarterly Consolidated
vs Q4 FY25
Shree Ganesh Remedies Limited Reports Q1FY26 Results: Revenue Down by 0.45% YoY
02 Aug 2025 · 2 Aug 2025, 02:17 pm
Summary
Shree Ganesh Remedies Limited, a fast-growing CMO & CDMO based in India for Pharmaceutical Intermediates & Fine Chemicals, announced its financial results for Q1FY26. The company reported a decrease in revenue and profitability compared to the previous year, primarily due to the repricing of contracts within the CRAMS business and headwinds in the European market. Despite these challenges, the company remains optimistic about the long-term prospects of its CRAMS vertical and is investing in new projects and infrastructure to support future growth.
Key Highlights
- 1
Revenue down by 0.45% YoY
- 2
EBITDA down by 10.19% YoY
- 3
Profit After Tax (PAT) down by 26.09% YoY
- 4
Contract repricing in CRAMS business
- 5
Continuing headwinds in the European market
- 6
Intensifying competition in domestic markets
- 7
Establishing a new pilot facility
- 8
Accelerated construction schedule for Block 7 at Dahej site
- 9
Focus on building necessary infrastructure for future growth
Management Comments
Mr. Gunjan Kothia
Promoter, Whole-Time Director
In line with our previously communicated guidance, SGRL Limited’s performance for Q1FY26 reflected a moderation in growth. This outcome was primarily driven by the repricing of contracts within our CRAMS business, combined with the continuing headwinds in the European market and intensifying competition in the domestic markets. The contract repricing also impacted our profitability, leading to a moderation in EBITDA margins, which now represent a more normalised and sustainable level compared to the elevated margins observed in the prior year. Despite these near-term challenges, our conviction in the long-term prospects of our CRAMS vertical remains robust. We are actively engaged in multiple new projects with both established and marquee clients, strengthening our pipeline for future growth. To expedite execution, we are establishing a new pilot facility, slated for completion within this quarter, which will enhance our ability to bring innovative solutions to market more rapidly. Additionally, with improved project visibility, we have accelerated the construction schedule for Block 7. At our Dahej site, progress is proceeding as planned. Our focus in FY26 will remain on building the necessary infrastructure to support a significant scale-up, positioning SGRL for a leap forward in the coming years.
Informational and educational content only. Not investment advice.